NCT02703571 - Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 29, 2016

Primary Completion Date

September 24, 2019

Study Completion Date

September 24, 2019

Conditions

Solid Tumors for Phase IbPancreatic Cancer for Phase IIColorectal Cancer for Phase II

Interventions

DRUG

ribociclib

Combination treatment with LEE and TMT

DRUG

Trametinib

Combination treatment with LEE and TMT

Trial Locations (15)

Novartis Investigative Site, Melbourne

Novartis Investigative Site, Leuven

University of Miami Sylvester Comp Cancer Ctr, Miami

Novartis Investigative Site, Cologne

Highlands Oncology Group, Fayetteville

UT MD Anderson Cancer Center, Houston

Novartis Investigative Site, Ulm

City of Hope National Medical Center, Duarte

Yale University School of Medicine, New Haven

Dana Farber Cancer Center, Boston

Novartis Investigative Site, Edmonton

Novartis Investigative Site, Vancouver

Novartis Investigative Site, Amsterdam

Novartis Investigative Site, Utrecht

Novartis Investigative Site, Barcelona